Sarah E. Kargbo-Hill

Sarah E. Kargbo-Hill

Auto-generated profile, based on publicly available information

Sarah E. Kargbo-Hill

National institute of Neurological Disorders and Stroke, NIH, Bethesda, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Nature
Verified
Journal Article
Open access
PDF file
ABAnna-Leigh Brown
Anna-Leigh Brown
OWOscar G. Wilkins
Oscar G. Wilkins
MKMatthew J. Keuss
Matthew J. Keuss
SHSarah E. Hill
Sarah E. Hill
MZMatteo Zanovello
Matteo Zanovello
PFPietro Fratta
Pietro Fratta
Variants of UNC13A, a critical gene for synapse function, increase the risk of amyotrophic lateral sclerosis and frontotemporal dementia1–3, two related neurodegenerative diseases defined by mislocalization of the RNA-binding protein TDP-434,5. Here we show that TDP-43 depletion induces robust inclusion of a cryptic exon in UNC13A, resulting in nonsense-mediated decay and loss of UNC13A protein. Two common intronic UNC13A polymorphisms strongly associated with amyotrophic lateral sclerosis and frontotemporal dementia risk overlap with TDP-43 binding sites. These polymorphisms potentiate cryptic exon inclusion, both in cultured cells and in brains and spinal cords from patients with these conditions. Our findings, which demonstrate a genetic link between loss of nuclear TDP-43 function and disease, reveal the mechanism by which UNC13A variants exacerbate the effects of decreased TDP-43 function. They further provide a promising therapeutic target for TDP-43 proteinopathies.

25 March 2021 in Nature
Verified
Journal Article
Closed access
PDF file
WWWei Wu
Wei Wu
SKSarah E. Kargbo-Hill
Sarah E. Kargbo-Hill
WNWilliam J. Nathan
William J. Nathan
JPJacob Paiano
Jacob Paiano
ECElsa Callen
Elsa Callen
ANAndré Nussenzweig
André Nussenzweig

2 November 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MPMercedes Prudencio
Mercedes Prudencio
JHJack Humphrey
Jack Humphrey
SPSarah Pickles
Sarah Pickles
ABAnna-Leigh Brown
Anna-Leigh Brown
SHSarah E. Hill
Sarah E. Hill
LPLeonard Petrucelli
Leonard Petrucelli
No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 (FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish between patients with FTLD-TDP and FTLD-tau. Therefore, we evaluated truncated stathmin-2 (STMN2) as a proxy of TDP-43 pathology, given the reports that TDP-43 dysfunction causes truncated STMN2 accumulation. Truncated STMN2 accumulated in human induced pluripotent stem cell–derived neurons depleted of TDP-43, but not in those with pathogenic TARDBP mutations in the absence of TDP-43 aggregation or loss of nuclear protein. In RNA-Seq analyses of human brain samples from the NYGC ALS cohort, truncated STMN2 RNA was confined to tissues and disease subtypes marked by TDP-43 inclusions. Last, we validated that truncated STMN2 RNA was elevated in the frontal cortex of a cohort of patients with FTLD-TDP but not in controls or patients with progressive supranuclear palsy, a type of FTLD-tau. Further, in patients with FTLD-TDP, we observed significant associations of truncated STMN2 RNA with phosphorylated TDP-43 levels and an earlier age of disease onset. Overall, our data uncovered truncated STMN2 as a marker for TDP-43 dysfunction in FTD.

1 July 2016 in Developmental Cell
Verified
Journal Article
Closed access
ASAndrea K.H. Stavoe
Andrea K.H. Stavoe
SKSarah E. Kargbo-Hill
Sarah E. Kargbo-Hill
DHDavid H. Hall
David H. Hall
DCDaniel A. Colón-Ramos
Daniel A. Colón-Ramos

14 February 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
SSSahba Seddighi
Sahba Seddighi
YQYue Andy Qi
Yue Andy Qi
ABAnna-Leigh Brown
Anna-Leigh Brown
OWOscar G. Wilkins
Oscar G. Wilkins
CBColleen Bereda
Colleen Bereda
MWMichael E. Ward
Michael E. Ward
Functional loss of TDP-43, an RNA binding protein genetically and pathologically linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), leads to the inclusion of cryptic exons in hundreds of transcripts during disease. Cryptic exons can promote the degradation of affected transcripts, deleteriously altering cellular function through loss-of-function mechanisms. Here, we show that mRNA transcripts harboring cryptic exons generated de novo proteins in TDP-43–depleted human iPSC–derived neurons in vitro, and de novo peptides were found in cerebrospinal fluid (CSF) samples from patients with ALS or FTD. Using coordinated transcriptomic and proteomic studies of TDP-43–depleted human iPSC–derived neurons, we identified 65 peptides that mapped to 12 cryptic exons. Cryptic exons identified in TDP-43–depleted human iPSC–derived neurons were predictive of cryptic exons expressed in postmortem brain tissue from patients with TDP-43 proteinopathy. These cryptic exons produced transcript variants that generated de novo proteins. We found that the inclusion of cryptic peptide sequences in proteins altered their interactions with other proteins, thereby likely altering their function. Last, we showed that 18 de novo peptides across 13 genes were present in CSF samples from patients with ALS/FTD spectrum disorders. The demonstration of cryptic exon translation suggests new mechanisms for ALS/FTD pathophysiology downstream of TDP-43 dysfunction and may provide a potential strategy to assay TDP-43 function in patient CSF.

1 April 2019 in Developmental Cell
Verified
Journal Article
Closed access
SKSarah E. Kargbo-Hill
Sarah E. Kargbo-Hill
KKKarlina J. Kauffman
Karlina J. Kauffman
MKMia Krout
Mia Krout
JRJanet E. Richmond
Janet E. Richmond
TMThomas J. Melia
Thomas J. Melia
DCDaniel A. Colón-Ramos
Daniel A. Colón-Ramos